CytRx (CYTR) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to CytRx (CYTR) Misses Q2 EPS by 8c

CytRx Reports Second Quarter 2016 Financial Results

July 29, 2016 9:01 AM EDT

LOS ANGELES, July 29, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended June 30, 2016, and provided an overview of recent corporate developments and upcoming milestones for its research and development programs.

"Our mission at CytRx is to bring new therapeutics to patients with cancer by applying our innovative Linker Activated Drug Release (LADR) technology to deliver cytotoxic payloads," said Steven A. Kriegsman, CytRx's Chairman and CEO.  "As we await the second analysis for our Phase 3... More